Articles tagged with Uterine Cancer
A NIH-funded research project has generated a comprehensive collection of patient-derived tumor models, covering 25 types of cancer from thousands of donor tissues. These models closely match their parental tumors in terms of genetic alterations and gene expression signatures, enabling researchers to explore tumor evolution and diversity.
A rare case of uterine carcinosarcoma was reported, characterized by a dual molecular signature that may refine prognosis and guide treatment decisions. The patient's tumor displayed a high-grade endometrioid homologous uterine carcinosarcoma with TP53 and MSH6 genetic alterations.
A cohort study of California educators found associations between trihalomethanes in drinking water and increased uterine cancer risk, including with endometrioid tumors. Further investigation is warranted to understand the role of drinking water contaminants as modifiable risk factors for this common gynecologic cancer.
The study found significant progress in reducing cancer mortality disparities for breast and uterine corpus cancers, but persistence in prostate cancer remains. The findings highlight the need for targeted interventions to accelerate progress in equitable cancer prevention and control.
A study of over 229,000 obese adults without diabetes found that weight loss drugs, such as semaglutide and tirzepatide, were associated with a 41% decrease in the overall risk of developing obesity-related cancers. GLP-1 RAs also showed larger reductions in certain subgroups, including men and gynaecologic cancers.
The NRG Oncology trial showed a sustained overall survival benefit for patients with advanced or recurrent endometrial cancer treated with pembrolizumab and chemotherapy, even after post-study immunotherapy. The benefit persisted in both mismatch repair proficient and deficient populations.
Researchers from Ohio State University Comprehensive Cancer Center present new findings on a hospital program that redistributes unused oral cancer drugs donated by patients. The program helps patients avoid treatment delays caused by insurance issues, shipping problems or cost, and has been shown to reduce drug delays by six days.
Researchers at the Sylvester Comprehensive Cancer Center presented several studies at ASCO 2026 exploring new treatment options for patients with advanced gastrointestinal stromal tumors (GISTs) and melanoma. These include velzatinib, a targeted therapy for GIST patients, and PRAME-directed T-cell receptor therapies for synovial sarcoma.
A large Australian study of over 417,000 women found that fertility treatments were not linked to higher overall cancer rates, but some cancers were slightly more common, while others were less common. Women who received fertility treatment were more likely to develop uterine and ovarian cancer, as well as melanoma, but the overall ris...
The King Center for Lynch Syndrome will advance research, outreach, education, and patient care for Lynch syndrome, a hereditary condition affecting 1 in 279 individuals. The center will provide cutting-edge research, life-long comprehensive care, and increased awareness for patients and families affected by Lynch syndrome.
A cohort study found combined GLP-1RA and progestin therapy reduces endometrial cancer risk in women with benign uterine pathology or endometrial hyperplasia. The study suggests potential benefits of this treatment approach for nonmalignant uterine diseases.
Researchers developed an AI tool called ONCO-ACS to predict the risk of secondary heart attacks in cancer patients after a heart attack. The tool combines cancer-related factors with standard clinical data to provide reliable information for doctors to balance treatment benefits and harms.
This study examines the association between genetic variants (GWAS loci) and environmental factors (reproductive history) in uterine fibroid development. Genetic variants like rs66998222 and rs11031731 are found to have context-specific effects, with some exhibiting protective or deleterious effects depending on abortion history.
A new study published in Diabetes, Obesity and Metabolism found that weight loss treatments, including medication and surgical procedures, may help lower the risk of obesity-related cancers in people with obesity and type 2 diabetes. The study analyzed data from over 180,000 people and found a significant reduction in cancer incidence ...
These rare tumors often present with aggressive behavior, early metastasis, and resistance to chemotherapy and radiotherapy. Early detection and disease staging are key factors associated with improved survival.
Researchers found tamoxifen encourages uterine cell growth and increases risk of secondary uterine cancer in breast cancer patients. The study suggests that blocking the PIK3 pathway could reduce this risk and potentially save lives.
Emerging evidence supports Mediterranean Diet and plant-based patterns in reducing endometrial cancer risk. The review also highlights the importance of physical activity, insulin sensitivity, and genetic stratification in personalized prevention frameworks.
A new case report documents a rare instance of lipoleiomyoma, a benign uterine tumor with characteristics similar to malignant liposarcoma. The diagnosis was confirmed through histopathological evaluation and imaging techniques, emphasizing the importance of careful assessment in elderly patients.
The study projects a significant increase in uterine cancer incidence and mortality rates in the US by 2050, with incidence-based mortality nearly three times higher in Black women compared to white women. The model also shows that obesity and hysterectomy rates will contribute to increased risks.
Researchers predict a substantial rise in uterine cancer incidence and deaths in the US, with a disproportionate impact on Black women. The study found that current trends will continue, with uterine cancer cases expected to increase by 50% in Black women versus 29% in white women.
A study found significant gaps in testing for genetic cancer risk among patients with womb cancer, with less than half eligible receiving a blood test for Lynch syndrome. This can lead to delayed diagnosis and increased cancer risk, affecting not only the individual but also their family members.
Combining immunotherapy drug dostarlimab with standard chemotherapy improved survival and reduced symptoms in patients with advanced endometrial cancer. Patients lived up to 5.5 months longer with fewer side effects, outweighing risks.
Two new predictive algorithms use health data and blood tests to identify high-risk patients, offering improved accuracy in diagnosing cancers. The models identified additional medical conditions associated with increased cancer risk and new symptoms indicative of multiple cancer types.
A new study reveals that over half of Black and Latina women reported using personal care products with formaldehyde-releasing preservatives, highlighting critical safety gaps in product regulation. The study found that these chemicals are present in a wide range of products, including shampoo, lotions, and eyelash glue.
Researchers from the University of Southampton engineered a new type of super-strong antibody that triggers a stronger response from the immune system compared to naturally produced antibodies. The study confirms that making subtle increases in rigidity stimulates immune activity, creating a powerful immune response against disease.
A new study reveals a cell atlas of the endometrium in women with PCOS, showing distinct differences in cellular composition and gene expression. The findings suggest that targeting specific cell types may lead to better treatment options for women with PCOS and related reproductive issues.
A combination therapy of FTH-001 (serabelisib) and FTH-003 (sapanisertib) with paclitaxel is being investigated in a Phase 2 trial for patients with advanced or recurrent endometrial cancer. The trial aims to target the PI3K/AKT/mTOR pathway, which is frequently mutated in cancer.
Breast cancer death rates are predicted to increase in EU patients aged 80 years and older, while falling in all other age groups. This is attributed to a lack of regular screening and access to modern treatments.
A rare case of adenomyosis in an 81-year-old postmenopausal woman closely resembles invasive endometrial cancer, emphasizing the challenges of diagnosing this condition. Further studies are needed to refine diagnostic protocols and determine risk factors for postmenopausal patients.
The FDA has revoked authorization for the use of Red Dye 3 in food and ingested drugs, citing studies linking it to cancer in laboratory male rats. This decision is an important step forward in addressing modifiable risk factors that have the potential to reduce cancer risk.
Researchers at MUSC Hollings Cancer Center have developed a new model for ovarian cancer that suggests serous uterine cancer may originate in the fallopian tubes, rather than the uterus. The model has already shown promising results in replicating high-grade serous ovarian and uterine cancers.
Researchers have found that natural killer cells instinctively recognize and attack the XPO1 protein, which drives cancer growth. By targeting this protein, scientists may be able to activate more killer cells to destroy cancer cells. The study suggests that this approach could lead to personalized cancer treatment with less side effects.
Obesity-related cancer rates in China have risen sharply among young people, with an alarming 3.6% annual increase between 2007 and 2021. The trend is particularly pronounced among those aged 25-29, highlighting the urgent need for better public health policies to address China's growing overweight and obesity rates.
Researchers discuss the use of antibody-drug conjugates (ADCs) in treating biologically aggressive tumors, such as uterine serous carcinoma. The ADC T-DXd has shown remarkable preclinical activity against primary USC cells lines and xenografts overexpressing HER2/neu.
A common diagnostic strategy for endometrial cancer can fail to catch the disease in 4-11% of Black patients, according to a new study. Tissue biopsies are recommended instead of transvaginal ultrasound for Black women with concerning symptoms.
A new AI-powered approach identifies a distinct subset of endometrial cancer with poorer survival rates, but would otherwise go unrecognized. The discovery will help doctors identify patients at high risk of recurrence and death, enabling more comprehensive treatment.
The RUBY Part 2 trial shows significant improvement in progression-free survival for patients with primary advanced or recurrent endometrial cancer treated with dostarlimab. Dostarlimab plus niraparib plus carboplatin/paclitaxel demonstrates a role for PARP inhibitor maintenance in improving patient outcomes.
A new study published in Oncotarget reveals a higher prevalence of germline BRCA1 and BRCA2 mutations in ovarian cancer patients from the Salento peninsula, with 28.6% having familial cases and 39.7% having sporadic cases. The study found that 29.8% of patients were carriers of BRCA1/2 mutation.
New research reveals that Black women are more likely to develop endometrial cancers called serous carcinoma and carcinosarcoma, which are more aggressive than those found in white women. The study also showed that Black patients have a higher risk of having copy number-high or TP53 abnormal tumors, which have worse outcomes.
A Phase III trial found that combining durvalumab and olaparib with chemotherapy reduces disease progression in advanced endometrial cancer patients by 45%, compared to 29% with durvalumab alone. The combination also shows benefits in MMR-proficient subgroups, offering new treatment options for these patients.
A large study of hair relaxer use among Black women found a significant association between frequent or long-term use and an increased risk of uterine cancer. Postmenopausal women who used chemical hair relaxers more than twice a year or for over five years had a greater than 50% increased risk.
Cancer cells exploit enhancer DNA to accelerate tumor growth, according to researchers at the University of Toronto. The study found that specific proteins regulate this process, suggesting potential treatments through FOXA1 or NFIB suppression.
Researchers have identified new genetic markers to detect Lynch syndrome-associated colorectal cancer with 92% accuracy. The discovery could lead to a non-invasive screening option using stool samples, reducing the need for annual colonoscopies and invasive tests.
A new study by Ohio State University found that most gynecologic cancer-related content on TikTok is poor in quality and accuracy. The majority of the content, over 73%, was deemed inaccurate and of poor educational quality, with racial disparities also present.
A large national study found that people with breast, ovarian, skin, and uterine cancers have higher levels of endocrine-disrupting chemicals like PFAS and phenols. The study suggests a link between these exposures and increased cancer risk in women. Researchers emphasize the need for EPA regulation to reduce PFAS exposure.
Researchers identified common bladder cancer-related mutations across species, including TP53, FAT1, and NRAS in cats, and ARID1A and KDM6A in dogs. This study provides insights into human MIBC and aids understanding of bladder cancer biology across species.
Researchers used base editors to introduce specific combinations of activating and inactivating mutations into healthy organoids, creating realistic models for various types of cancer. This allows for further investigation into the development and treatment of cancer, with potential applications including testing new drugs.
A study found disparities in Hispanic cancer mortality rates, with higher rates for men in certain age groups and women for liver, pancreatic, and uterine cancers. The researchers highlight the need for targeted education and screening efforts to address these disparities.
Researchers have developed a new technique to generically treat several kinds of cancer, showing tumors grew almost three times less and survival rates reached 100% after just one injection. The method targets cancer cells with alpha radiation, sparing healthy tissue.
Research by Sylvester Comprehensive Cancer Center reveals African-descent subpopulations worldwide have unique trends in endometrial cancer rates, influenced by diet, stress and socioeconomic factors. The study highlights the importance of focusing on specific regions to assess cancer risks for different population groups.
Researchers analyzed data on 34,789 endometrial cancer cases from Florida and the French Caribbean, finding that Caribbean Black women had the lowest rates for both subtypes. Non-endometrioid types were most common among US Black women, with rates increasing yearly for all groups.
Research from Johns Hopkins Medicine found that Black and Hispanic female breast cancer survivors have higher death rates from second cancers compared to other ethnic groups. The risk of death from a second cancer is 12% higher among non-Hispanic Black survivors and 8% higher among Hispanic survivors.
Researchers used cancer proteomics data to identify gene candidates for therapeutic targeting, focusing on protein kinases in uterine endometrial cancer cells. Public molecular resources and multi-omics data analysis can prioritize genes of interest for future studies.
The LY6 gene family has been found to be overexpressed in uterine corpus endometrial carcinoma (UCEC), leading to poor patient survival. Several LY6 genes have been identified as potential tumor-associated antigens and biomarkers for UCEC detection and prognosis.
A new study of over 200 people with premature aging syndromes caused by abnormally short telomeres suggests that chromosomal instability may not be the reason for increased cancer risk. Instead, immune system cells that age and die prematurely may play a role in cancer predisposition.
Researchers at University of California San Diego School of Medicine found a significant reduction in disease growth when combining immunotherapy with chemotherapy in patients with advanced endometrial cancer. The study resulted in a 70% risk reduction in the deficient mismatch repair group.
The ENGOT-EN6-NSGO/GOG-3031/RUBY trial reveals significant improvements in progression-free survival and overall survival for patients with primary advanced or recurrent endometrial cancer when treated with dostarlimab in combination with standard of care carboplatin/paclitaxel. The new treatment regimen offers a substantial increase i...
A team of scientists has identified Myo5b as a potential genetic driver of uterine corpus endometrial cancer (UCEC), a fourth deadliest cancer in women. Elevated levels of Myo5B were found in UCEC samples, suggesting its role in transporting nutrient-absorbing transporters to the surface of cancer cells.
The ESMO Gynaecological Cancers Congress 2023 will present the latest treatments and insights for ovarian, uterine, cervical, and rare gynaecological cancers. Around 80 studies will be presented on strategies to overcome PARP inhibitors mechanisms of resistance in ovarian cancer.
The ESMO Asia Congress 2022 will focus on the latest scientific and clinical advances in oncology, with a special emphasis on the Asia-Pacific region. Media representatives can register for coverage through the official media registration form.